CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway

Immunogenicity Assessment of Gene Therapy Compounds

Evaluating the Immunogenicity of Antibody–drug Conjugates

Strategies for Development and Validation of Neutralizing Antibody Assays Supporting Biosimilars

Clinical relevance of immunogenicity: an interview with Arno Kromminga

Exploratory biomarker testing: to qualify or validate the assay?

Immunogenicity Considerations for Antibody–drug Conjugates: A Focus on Neutralizing Antibody Assays

Bioanalysis Zone’s “Ask the Experts” Series on Biosimilars

Defining Best Practices for Biosimilar Development

Cell-Based Assays Keep Biosimilars on Track

Interview with Afshin Safavi (Founder & CSO, BioAgilytix) on biomarker analysis in support of preclinical and clinical studies

Meeting the rigorous demands of biosimilar pharmacokinetics

How to win client trust as a CRO

Running a successful CRO

How to set up a successful CRO by surrounding yourself with the right team members

Starting a CRO on personal credit

Parallelism and Matrix Interference: The Importance of Nomenclature (Part 1)

Growing Clinical Biomarker Assays

Development and validation of an alpha fetoprotein immunoassay using Gyros technology

Implementation of a universal analytical method in early-stage development of human antibody therapeutics

Validation of a Gyrolab™ assay for quantification of rituximab in human serum

Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis